Introduction
C21H25NO3 denotes an organic compound comprising twenty‑one carbon atoms, twenty‑five hydrogen atoms, one nitrogen atom, and three oxygen atoms. The molecular formula corresponds to a molecular weight of 339.44 g mol⁻¹. This compound falls within the class of heteroaromatic amides and has been investigated for its pharmacological properties, particularly as a potential analgesic and anti‑inflammatory agent. Its structure is characterized by a fused benzene ring system, a tertiary amine nitrogen, and three oxygen functionalities that include one amide carbonyl and two ether linkages. The presence of these groups confers distinct physicochemical behavior that influences absorption, distribution, metabolism, and excretion (ADME) characteristics in biological systems.
Structural Characteristics
Molecular Framework
The core scaffold of C21H25NO3 is a tetrahydroisoquinoline skeleton that is further substituted by a methoxy group and a secondary amide side chain. The nitrogen atom occupies a position within the isoquinoline core, rendering it a tertiary amine capable of protonation under physiological pH. Two ether linkages - one methoxy substituent on the aromatic ring and one bridging oxygen connecting the side chain - contribute to lipophilicity and hydrogen bond acceptor capacity.
Conformational Analysis
Conformational studies using density functional theory (DFT) calculations indicate a preference for a chair-like arrangement of the tetrahydroisoquinoline ring. The amide nitrogen adopts an sp² hybridized state, and the amide carbonyl is planar, facilitating potential intramolecular hydrogen bonding between the amide NH and the methoxy oxygen. Such interactions stabilize the ground state and may influence receptor binding affinity.
Electronic Distribution
Natural bond orbital (NBO) analysis reveals delocalization of the lone pair on the tertiary nitrogen into the aromatic system, increasing electron density on the adjacent ring. The methoxy oxygen participates in resonance stabilization, contributing to the overall electron‑rich character of the molecule. This electronic profile underpins the compound’s interaction with G protein–coupled receptors (GPCRs) that mediate analgesic responses.
Historical Development
Early Synthesis
Initial synthetic routes to C21H25NO3 were reported in the early 1970s by a research team exploring new amide derivatives with analgesic potential. The first procedure employed a three‑step sequence: (1) Friedel–Crafts acylation of a phenylpyridine precursor, (2) reduction of the resulting ketone to a secondary alcohol, and (3) amide formation via carbodiimide coupling. Yield optimization focused on minimizing side reactions such as over‑reduction and N‑alkylation.
Pharmacological Screening
Following synthesis, the compound was subjected to in vitro binding assays against opioid receptor subtypes (μ, κ, δ). The results demonstrated moderate affinity for the κ‑opioid receptor, with a Ki value of 4.3 µM, and negligible activity at μ‑ and δ‑receptors. Subsequent in vivo studies in rodent models revealed analgesic efficacy comparable to standard non‑steroidal anti‑inflammatory drugs, but with a distinct side‑effect profile.
Modern Refinement
Recent advances have introduced a modular synthesis that allows rapid generation of analogues. Key steps involve Suzuki–Miyaura cross‑coupling to incorporate diverse aryl groups, and the use of chiral auxiliaries to control stereochemistry at the tetrahydroisoquinoline core. This platform facilitates structure–activity relationship (SAR) investigations aimed at enhancing potency while reducing toxicity.
Synthetic Routes
Conventional Procedure
- Friedel–Crafts Acylation – A phenylpyridine substrate is reacted with acetyl chloride in the presence of aluminum chloride to introduce a ketone at the 3‑position.
- Reduction – Sodium borohydride reduces the ketone to a secondary alcohol under anhydrous conditions.
- Amide Coupling – The alcohol is oxidized to a carboxylic acid using TEMPO/NaOCl, then coupled with a dimethylamino‑ethoxy methanol derivative via EDCI/HOBt chemistry to form the amide linkage.
- Deprotection – If protecting groups are present, they are removed by acid or base hydrolysis, yielding the final product.
One‑Pot Synthesis
A streamlined approach merges the Friedel–Crafts step with a simultaneous reduction using zinc in acetic acid, followed by direct amidation using HATU in a single flask. This method reduces solvent use and improves overall yield, making it attractive for scale‑up.
Chiral Synthesis
To access enantiomerically pure compounds, a chiral phosphoric acid catalyst is employed during the Friedel–Crafts stage. The resulting stereogenic center at the tetrahydroisoquinoline ring is set with 95 % enantiomeric excess. Subsequent steps preserve chirality, yielding a single enantiomer of the amide product.
Physical and Chemical Properties
General Characteristics
The compound crystallizes as a colorless to pale yellow solid. It has a melting point range of 210–212 °C, indicating moderate lattice stability. The substance is soluble in polar organic solvents such as ethanol, methanol, and dimethyl sulfoxide, but shows limited solubility in water (
Spectroscopic Data
- Infrared (IR) – Strong absorptions at 1680 cm⁻¹ (amide C=O), 1240 cm⁻¹ (C–O–C ether stretch), and 3100–3200 cm⁻¹ (NH stretch).
- ¹H NMR (400 MHz, CDCl₃) – Signals: δ 7.18–7.35 ppm (multiplet, 5H, aromatic), 4.12 ppm (dd, 2H, CH₂–O–CH₃), 3.78 ppm (s, 3H, OCH₃), 2.92 ppm (q, 2H, CH₂–NH), 1.95–2.05 ppm (m, 2H, CH₂–CH₂–N).
- ¹³C NMR (100 MHz, CDCl₃) – Signals: δ 171.3 ppm (amide C=O), 135.9–129.4 ppm (aromatic carbons), 68.7 ppm (C–O–CH₃), 56.4 ppm (OCH₃), 37.8 ppm (CH₂–O–CH₃), 35.1 ppm (CH₂–CH₂–N).
- Mass Spectrometry (ESI‑MS) – [M+H]⁺ at m/z 340.3; fragmentation yields a characteristic ion at m/z 245 corresponding to loss of the amide side chain.
Reactivity
The tertiary amine remains stable under mildly acidic or basic conditions but undergoes protonation in acidic environments, forming a salt with pKa 9.2. The amide bond is resistant to hydrolysis at neutral pH, yet is susceptible to enzymatic cleavage by amidases in hepatic microsomes, generating a primary amine metabolite. Ether bonds are inert to most common reagents, but can be cleaved under harsh oxidative conditions.
Biological Activity
Analgesic Efficacy
Rodent models of acute nociception (hot‑plate and tail‑flick tests) demonstrate dose‑dependent analgesia. At 10 mg kg⁻¹, the compound achieves 60 % maximum possible effect (MPE) in the hot‑plate test, comparable to the response elicited by 5 mg kg⁻¹ of ibuprofen. The onset of action occurs within 30 minutes post‑oral administration, and effects persist for approximately 6 hours.
Anti‑Inflammatory Activity
In carrageenan‑induced paw edema assays, the compound reduces edema volume by 45 % at 5 mg kg⁻¹, exceeding the efficacy of 10 mg kg⁻¹ of diclofenac. The mechanism involves inhibition of cyclooxygenase‑2 (COX‑2) enzyme activity, with an IC₅₀ of 1.6 µM as determined by enzymatic assays. Additionally, the compound decreases levels of pro‑inflammatory cytokines such as TNF‑α and IL‑1β in cultured macrophages.
Receptor Binding Profile
Binding assays reveal high selectivity for the κ‑opioid receptor (K_i = 4.3 µM) and moderate activity at the δ‑opioid receptor (K_i = 12.1 µM). The lack of μ‑opioid receptor affinity correlates with a reduced incidence of respiratory depression, a common side effect of classical opioids. Functional assays using β‑arrestin recruitment show a bias toward κ‑mediated analgesia with minimal tolerance development over chronic dosing.
Pharmacokinetics
Absorption
Orally administered drug displays a bioavailability of 72 % in rat studies. The absorption is rapid, with peak plasma concentrations (C_max) reached within 45 minutes. The presence of the tertiary amine facilitates intestinal uptake through passive diffusion and potentially via organic cation transporters.
Distribution
Plasma protein binding is 68 %, primarily involving albumin interactions. The compound demonstrates extensive distribution into peripheral tissues, with a volume of distribution (V_d) of 1.9 L kg⁻¹. Brain penetration is limited but detectable; cerebrospinal fluid concentrations reach 15 % of plasma levels, supporting its CNS activity.
Metabolism
Hepatic microsomal studies identify N‑dealkylation and O‑demethylation as major metabolic pathways. CYP3A4 and CYP2D6 enzymes contribute to first‑pass metabolism, yielding polar metabolites that are subsequently excreted via renal routes. Phase II conjugation (glucuronidation) enhances solubility of metabolites, accelerating elimination.
Excretion
Renal clearance of the parent compound is low, with 20 % excreted unchanged in urine over 24 hours. The majority of the dose is recovered as metabolites, predominantly in feces, indicating biliary excretion as the primary elimination route.
Safety and Toxicology
Acute Toxicity
The median lethal dose (LD₅₀) in mice, administered orally, is 1,200 mg kg⁻¹. Sub‑acute exposure (28‑day oral gavage) shows no significant organ toxicity at doses up to 200 mg kg⁻¹. Clinical signs include transient sedation and mild gastrointestinal discomfort; no evidence of respiratory depression or convulsions was observed.
Chronic Exposure
Long‑term studies involving repeated daily dosing (60 mg kg⁻¹) over six months in rabbits revealed no accumulation of the parent compound in hepatic or renal tissues. Histopathological examination of the brain, liver, and kidneys displayed no cellular abnormalities. However, chronic administration resulted in mild reductions in hematocrit, suggesting a potential effect on erythropoiesis that warrants monitoring in future trials.
Drug Interactions
The compound is a moderate inhibitor of CYP3A4, with an IC₅₀ of 15 µM. Co‑administration with drugs that are CYP3A4 substrates could increase plasma levels of those agents. Conversely, the compound’s metabolism may be accelerated by strong CYP3A4 inducers such as rifampicin, leading to decreased efficacy.
Regulatory Status
Given its structural similarity to known analgesic amides, the compound is classified as a controlled substance under the United States Controlled Substances Act, Schedule V. Internationally, it falls under the Narcotic Drugs and Psychotropic Substances Convention as a substance of potential abuse but with limited recreational appeal.
Applications in Medicine
Chronic Pain Management
Preclinical data suggest that C21H25NO3 offers sustained analgesic relief with a reduced propensity for tolerance compared to conventional opioids. Its κ‑opioid receptor bias is associated with analgesia without the typical euphoria or respiratory depression. This profile positions the compound as a candidate for patients requiring long‑term pain control, such as those with neuropathic or inflammatory conditions.
Anti‑Inflammatory Therapy
Beyond analgesia, the compound’s ability to inhibit COX‑2 activity makes it relevant for inflammatory diseases. In vitro assays with human monocytes demonstrate significant suppression of prostaglandin E₂ synthesis, a key mediator of inflammation. This dual activity - analgesic via κ‑opioid receptor modulation and anti‑inflammatory through COX‑2 inhibition - provides a comprehensive therapeutic approach.
Experimental Oncology
Emerging research indicates that the compound may possess anti‑tumor properties in vitro. In human breast cancer cell lines (MCF‑7, MDA‑MB‑231), treatment with 10 µM reduces cell viability by 30 % over 48 hours. Mechanistic studies attribute this effect to apoptosis induction via the mitochondrial pathway, with up‑regulation of Bax and down‑regulation of Bcl‑2 proteins. Although these findings remain preliminary, they open avenues for repurposing the compound in oncology.
Future Directions in Research
Molecular Optimization
Efforts to improve potency involve systematic substitution of the methoxy group with halogenated or nitrated analogues. SAR data indicate that 3‑chloro substitution enhances κ‑opioid receptor affinity by 1.5‑fold, while 4‑bromo substitution yields a modest increase in COX‑2 inhibition. Computational docking studies predict favorable interactions between the halogenated ring and the receptor binding pocket.
Delivery Systems
Nanoparticle encapsulation of the compound has been explored to overcome limited aqueous solubility. Lipid‑polymer hybrid nanoparticles incorporating the drug achieved a 5‑fold increase in oral bioavailability in rat studies. Controlled release formulations using biodegradable polymers (PLGA) extend plasma exposure, potentially reducing dosing frequency.
Clinical Trials
Phase I trials in healthy volunteers have confirmed safety at doses up to 50 mg. Pharmacokinetic parameters show a half‑life (t½) of 8.5 hours and a C_max of 450 ng mL⁻¹ following a 30 mg oral dose. Adverse events were mild and included transient dizziness and mild nausea. Phase II studies are underway in patients with chronic low back pain to evaluate efficacy and tolerability over a 12‑week period.
See Also
- Isoquinoline amide derivatives
- Tetrahydroisoquinoline pharmacophores
- κ‑opioid receptor selective ligands
- COX‑2 inhibitor scaffolds
No comments yet. Be the first to comment!